Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study

Autor: Jens Benn Sørensen, Paul Baas, Szimonetta Komjáthiné Szépligeti, Alma B. Pedersen, Søren P. Johnsen, Robert Carroll, Minouk J. Schoemaker, Caroline Rault, Melinda J. Daumont, Vera Ehrenstein

Publikováno v: Acta Oncologica, Vol 63, Iss 1 (2024)

Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved outcomes; however, real-world evidence on its use will take time to accumulat

Externí odkaz: https://doaj.org/article/12feb6552e244e149a6d6c1e2c4ce6c3

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study

Autor: Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont

Publikováno v: Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746

Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b22e89285ed49f2426766efa430dd83d
https://doi.org/10.2217/fon-2021-0746

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

Autor: Ida Kappel Buhl, Eric Santoni-Rugiu, Jesper Ravn, Anker Hansen, Ib Jarle Christensen, Thomas Jensen, Bruce Pratt, Jon Askaa, Peter Buhl Jensen, Steen Knudsen, Jens Benn Sørensen

Publikováno v: PLoS ONE, Vol 13, Iss 3, p e0194609 (2018)

Effective predictive biomarkers for selection of patients benefiting from adjuvant platinum-based chemotherapy in non-small cell lung cancer (NSCLC) are needed. Based on a previously validated methodology, molecular profiles of predicted sensitivity

Externí odkaz: https://doaj.org/article/fa1ec23de6bb4b5588af6657dd77f122

Very Early Response Evaluation by PET/MR in Patients with Lung Cancer—Timing and Feasibility

Autor: Natasha Hemicke Langer, Seppo W. Langer, Helle Hjorth Johannesen, Adam Espe Hansen, Junia Costa, Thomas Levin Klausen, Julie Forman, Anders Olin, Sine Hvid Rasmussen, Jens Benn Sørensen, Johan Löfgren, Andreas Kjær, Barbara Malene Fischer

Publikováno v: Diagnostics, Vol 9, Iss 1, p 35 (2019)

Purpose: With the increasing number of therapy options available for patients with lung cancer, early response evaluation is needed. We performed this pilot study to assess the feasibility of early, repeated Positron emission tomography-magnetic reso

Externí odkaz: https://doaj.org/article/851a0dcdb5f7481e94cdb58c19e91b7a

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC

Autor: Eric Santoni-Rugiu, Jens Benn Sørensen, Linea Melchior, E. Urbanska, Junia Costa

The unavoidable progression of EGFR-mutated NSCLC on EGFR-TKIs forces us to discover solutions for further therapies. Herein, we discuss the necessity of accurate genomic mapping of progressive disease illustrated by a patient case. Tumor rebiopsies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f72e57f61b8220b080bb1db47fd6aa70